close
Trend Chart On Innovative Biotherapies March 28th
©M-Pinarci-via-Visualhunt
News

Trend Chart On Innovative Biotherapies March 28th

FEATURE STORY
Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies
GENE THERAPY
Permanent inactivation of HBV genomes by CRISPR/Cas9-mdediated non cleavage base editing
DISRUPTIVE TECHNOLOGIES
● Hydroxybutyl chitosan centered biocomposites for potential curative applications
● CAR-T treatment for hematological malignancies
● Anti-CRISPRs : Protein inhibitors of the CRISPR-Cas systems
● Russian company BIOCAD started working on mRNA vaccine against coronavirus
C
LINICAL TRIALS – DATA
●  Onasemnogene Abeparvovec-xioi: gene therapy for Spinal Muscular Atrophy
● First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and hematologic tumors
INDUSTRIAL LANDSCAPE & AGREEMENTS
● AstraZeneca pays Silence $60M to take siRNA beyond the liver
● Horama signs exclusive license agreement with Leiden University Medical Center targeting CRB1 gene mutations to treat inherited retinal dystrophies
MISCELLANEOUS
● The ‘Netflix plus model’: can subscription financing improve access to medicines in low- and middle-income countries?

To read the full articles, click here: Trend Chart on Innovative Biotherapies


COMMENTS ARE OFF THIS POST